top of page

We redefine


Our Ambition

plusbiome is pioneering a new class of anticancer medicines to deliver superior therapy outcomes compared to current treatment options.


We are validating pathways between the gut microbiome and the immune system. Our therapeutic ambition is to regulate selectively these mechanisms to drive effective anti-cancer immunity. Changing lives of cancer patients and their families for the better.

“There is no disease that is not linked to the microbiome”

Nature biotech conference 2021

Pipetting Samples

Our Science

By focusing on the immune conditioning of the microbiome in cancer therapies we develop our portfolio of assets, which we are validating in pre-clinical studies.

bottom of page